ObsEva SA

Mutation ObsEva SA

Rubrik: Handelsregistereintragungen
Unterrubrik: Mutation
Grund: Diverse Änderungen

ObsEva SA, à Plan-les-Ouates, CHE-253.914.856 (FOSC du 09.02.2024, p. 0/1005958053). Edfjäll Eva Catarina n'est plus administratrice; ses pouvoirs sont radiés.

SHAB: 78 vom 23.04.2024
Tagesregister: 7694 vom 18.04.2024
Meldungsnummer: HR02-1006016063
Kantone: GE

Mutation ObsEva SA

Rubrik: Handelsregistereintragungen
Unterrubrik: Mutation
Grund: Diverse Änderungen

ObsEva SA, à Plan-les-Ouates, CHE-253.914.856 (FOSC du 26.07.2023, p. 0/1005804768). Selon jugement du Tribunal de première instance du 29.01.2024, octroi d'un sursis concordataire provisoire jusqu'au 29.05.2024.

Commissaire provisoire au sursis:
Zölly Philippe, de Zurich, à Meinier.

SHAB: 28 vom 09.02.2024
Tagesregister: 2682 vom 06.02.2024
Meldungsnummer: HR02-1005958053
Kantone: GE

Mutation ObsEva SA

Rubrik: Handelsregistereintragungen
Unterrubrik: Mutation
Grund: Diverse Änderungen

ObsEva SA, à Plan-les-Ouates, CHE-253.914.856 (FOSC du 06.06.2023, p. 0/1005762121). Suppression de la clause d'augmentation autorisée du capital-actions décidée par l'assemblée générale du 18.05.2022. L'assemblée générale a introduit une clause statutaire relative à une marge de fluctuation du capital-actions par décision du 29.06.2023; pour les détails, voir les statuts. La clause d'augmentation conditionnelle du capital-actions décidée par l'assemblée générale du 28.05.2021 a été modifiée selon décision du 29.06.2023; pour les détails voir les statuts. Statuts modifiés le 29.06.2023, ainsi que sur des points non soumis à publication. Brown Stephanie, Mathers Edward, Vanlent Anne Marie et O'Callaghan Brian Thomas ne sont plus administrateurs; les pouvoirs de Brown Stephanie, Mathers Edward et Vanlent Anne Marie sont radiés. Lefebvre de Ladonchamps Fabien, jusqu'ici directeur, est maintenant administrateur. Marro Luigi, jusqu'ici directeur, est maintenant administrateur.

SHAB: 143 vom 26.07.2023
Tagesregister: 13865 vom 21.07.2023
Meldungsnummer: HR02-1005804768
Kantone: GE

1. Approval of the Management Report, the Statutory Financial Statements and the Consolidated Financial Statements for Fiscal Year 2022. The Board of Directors proposes that the management report, the statutory financial statements and the consolidated financial statements of ObsEva SA for fiscal year 2022 be approved.

2. Discharge of Liability for the Members of the Board of Directors and of the Executive Committee. The Board of Directors proposes that shareholders release the members of the Board of Directors and of the Executive Committee from liability for their activities during fiscal year 2022.

3. Appropriation of Financial Results. The Board of Directors proposes that the loss of USD 36,373,527 for the financial year 2022 be appropriated as follows:

Financial Year 2022

Accumulated losses brought forward from previous year

USD 383,931,623

Net loss for the year 2022

USD 36,373,527

Accumulated losses to be carried forward

USD 420,305,150

4. Elections to the Board of Directors and Election of the Chairman of the Board of Directors. The Board of Directors proposes the re-election, respectively re-election, of the following nominees for a term of one year expiring at the closing of the 2024 Annual General Meeting:

4.1. Re-election of Ernest Loumaye as Member of the Board of Directors and election as Chairman of the Board of Directors (in a single vote)

4.2. Re-election of Catarina Edfjäll as Member of the Board of Directors

4.3. Election of Luigi Marro as Member of the Board of Directors

Luigi Marro served as Chief Transformation Officer of ObsEva from October 2021 to February 2023. Mr. Marro is a pharmaceutical and biotech executive with over 20 years of experience. He has a background in finance and operations and has managed global businesses across multiple therapeutics areas from development stages through commercialization. Prior to joining ObsEva, Mr. Marro founded in February 2019 his own consulting company, Martan Market GmbH, to support biotech and pharma startups. From May 2014 to February 2019, he served as Chief Financial Officer at Finox Biotech, which launched the first biosimilar recombinant follicle stimulating hormone (r-FSH) product to market. From November 2012 to July 2013, Luigi held leadership positions at Voisin Life Sciences Consulting SA as Chief Operating Officer. He also acted as Senior Director Strategy Development and Business Performance at Merck Serono from January 2010 to October 2012. Mr. Marro also held elevating several strategic roles at Serono, prior to its acquisition by Merck. Mr. Marro holds a university degree in Demographic and Economical Statistic Sciences from La Sapienza in Rome as well as a Master of Business Administration from Luiss Management school in Rome.

4.4. Election of Fabien de Ladonchamps as Member of the Board of Directors

Fabien de Ladonchamps is a biotech executive with 25 years of experience in finance and administrative roles, primarily with Swiss biotech companies. Mr. de Ladonchamps has been appointed Chief Executive Officer of ObsEva in May 2023. Prior to that, he was a member of ObsEva's Executive Committee from October 2013 to July 2022, during which he had held the roles of Chief Administrative Officer and Interim Chief Financial Officer. He also served as the sole finance and accounting officer for the Company for a total of four years during which over $110 Million in equity proceeds were raised through private and public financing rounds. Mr. de Ladonchamps was instrumental in the Company's listings on both Nasdaq in 2017 and the Swiss Exchange in 2018. Prior to joining ObsEva, Mr. de Ladonchamps held a variety of management roles at Addex Therapeutics, from 2008 to 2013. Mr. de Ladonchamps holds a degree in Finance and Accounting from the Lyon III University in Lyon, France.

Stephanie Brown, Anne VanLent, Edward Mathers and Brian O'Callaghan are not standing for re-election.

5. Elections to the Compensation Committee. The Board of Directors proposes the election, respectively re-election, of the following nominees for a term of one year expiring at the closing of the 2024 Annual General Meeting:

5.1. Re-election of Catarina Edfjäll as Member of the Compensation Committee

5.2. Election of Ernest Loumaye as Member of the Compensation Committee

6. Re-election of PricewaterhouseCoopers SA as ObsEva SA's Auditors. The Board of Directors proposes the re-election of PricewaterhouseCoopers SA as ObsEva SA's auditors for the fiscal year 2023.

7. Re-election of Perréard de Boccard SA as Independent Representative. The Board of Directors proposes the re-election of Perréard de Boccard SA, Rue de la Coulouvrenière 29, 1204 Genève, as Independent Representative of shareholders for a one-year term expiring at the closing of the 2024 Annual General Meeting.

8. Compensation of the Board of Directors and the Executive Committee

8.1. Consultative vote on the Compensation Report 2022. The Board of Directors proposes that the compensation report 2022 be accepted (consultative vote).

8.1. Approval of the Compensation of the Board of Directors. The Board of Directors proposes that the shareholders approve a maximum aggregate amount of compensation of CHF 1,250,000 for the members of the Board of Directors for the period from the 2023 Annual General Meeting to the 2024 Annual General Meeting.

8.2. Approval of the Compensation of the Executive Committee for the Fiscal Year 2024. The Board of Directors proposes that the shareholders approve a maximum aggregate amount of compensation of CHF 1,500,000 for the members of the Executive Committee for the fiscal year 2024.

9. Introduction of a Capital Band and Related Amendments to the Articles of Association. The Board of Directors proposes to delete the current Article 5a relating to the authorized capital and to introduce a new Article 5a relating to a capital band of 72,933,302 fully paid-in registered shares with a par value of CHF 1/13 of a franc each, ranging from CHF 11,220,508 and 1/13 of a franc (lower limit) to CHF 16,830,762 and 1/13 of a franc (upper limit), so that the Board of Directors be authorized to increase ObsEva SA's share capital within the capital band, at once or in several times, until 29 June 2028, unless the capital band lapses at an earlier date, and to amend the Articles of Association accordingly.

10. Increase of ObsEva SA's Conditional Share Capital for Financing Purposes. The Board of Directors proposes to increase by 35,869,210, corresponding to an increase from 18,598,619 to 54,467,829, the number of new ordinary shares that can be issued upon exercise of option and conversion rights that may be granted in connection with bonds, similar debt instruments, loans or other financial market instruments or contractual obligations of the Company or one of its subsidiaries, and/or upon exercise of option rights issued by the Company or one of its subsidiaries, and to amend the Articles of Association accordingly.

For the Board of Directors

Ernest Loumaye, Chairman of the Board

Mutation ObsEva SA

Rubrik: Handelsregistereintragungen
Unterrubrik: Mutation
Grund: Diverse Änderungen

ObsEva SA, à Plan-les-Ouates, CHE-253.914.856 (FOSC du 23.05.2023, p. 0/1005752302). Les pouvoirs de Brown William sont radiés. Signature collective à deux a été conférée à Lefebvre de Ladonchamps Fabien, de France, à Seynod, FRA, directeur.

SHAB: 107 vom 06.06.2023
Tagesregister: 10397 vom 01.06.2023
Meldungsnummer: HR02-1005762121
Kantone: GE

Mutation ObsEva SA

Rubrik: Handelsregistereintragungen
Unterrubrik: Mutation
Grund: Diverse Änderungen

ObsEva SA, à Plan-les-Ouates, CHE-253.914.856 (FOSC du 13.12.2022, p. 0/1005627409). Clancy Annette n'est plus administratrice; ses pouvoirs sont radiés. Les pouvoirs de Bertram Clive David, Bührer Katja et Howard Brandon sont radiés. L'administrateur Loumaye Ernest, nommé président, continue à signer collectivement à deux. L'administrateur O'Callaghan Brian Thomas, jusqu'ici délégué, n'exerce plus la signature.

SHAB: 98 vom 23.05.2023
Tagesregister: 9508 vom 17.05.2023
Meldungsnummer: HR02-1005752302
Kantone: GE

Mutation ObsEva SA

Rubrik: Handelsregistereintragungen
Unterrubrik: Mutation
Grund: Kapital neu

ObsEva SA, à Plan-les-Ouates, CHE-253.914.856 (FOSC du 25.11.2022, p. 0/1005613550). Augmentation conditionnelle du capital-actions, fondée sur la décision relative à l'octroi de droits du 18.05.2022, porté de CHF 8'355'420, 85 à CHF 9'682'046, 54 par l'émission de 17'246'134 actions de 1/13 de CHF 1, nominatives. Augmentation autorisée du capital-actions, fondée sur la décision d'autorisation du 18.05.2022, porté de CHF 9'682'046, 54 à CHF 11'220'508, 08 par l'émission de 20'000'000 actions de 1/13 de CHF 1, nominatives.

Capital-actions:
CHF 11'220'508, 08, entièrement libéré, divisé en 145'866'605 actions de 1/13 de CHF 1, nominatives. Statuts modifiés le 08.12.2022.

SHAB: 242 vom 13.12.2022
Tagesregister: 22677 vom 09.12.2022
Meldungsnummer: HR02-1005627409
Kantone: GE

Mutation ObsEva SA

Rubrik: Handelsregistereintragungen
Unterrubrik: Mutation
Grund: Diverse Änderungen

ObsEva SA, à Plan-les-Ouates, CHE-253.914.856 (FOSC du 21.11.2022, p. 0/1005609465). Verwiel Franciscus n'est plus administrateur; ses pouvoirs sont radiés. Les pouvoirs de Garner Elizabeth Ijeoma Onyemelukwe et Lefebvre de Ladonchamps Fabien sont radiés. Clancy Annette, nommée présidente, continue à signer collectivement à deux. Brown Stephanie, du Canada, à Boston, USA, est membre du conseil d'administration avec signature collective à deux. Signature collective à deux a été conférée à Howard Brandon, des USA, à Yardley, USA, directrice.

SHAB: 230 vom 25.11.2022
Tagesregister: 21398 vom 22.11.2022
Meldungsnummer: HR02-1005613550
Kantone: GE

Mutation ObsEva SA

Rubrik: Handelsregistereintragungen
Unterrubrik: Mutation
Grund: Diverse Änderungen

ObsEva SA, à Plan-les-Ouates, CHE-253.914.856 (FOSC du 03.06.2022, p. 0/1005488606). Les pouvoirs de Gotteland Jean-Pierre sont radiés.

SHAB: 226 vom 21.11.2022
Tagesregister: 21005 vom 16.11.2022
Meldungsnummer: HR02-1005609465
Kantone: GE

Mutation ObsEva SA

Rubrik: Handelsregistereintragungen
Unterrubrik: Mutation
Grund: Diverse Änderungen

ObsEva SA, à Plan-les-Ouates, CHE-253.914.856 (FOSC du 11.04.2022, p. 0/1005448445). Par décision du 18.05.2022, l'assemblée générale a supprimé la clause statutaire relative à une augmentation autorisée du capital-actions introduite le 28.05.2021 et a introduit une nouvelle clause statutaire relative à une augmentation autorisée du capital-actions; pour les détails, voir les statuts (art. 5a). La clause d'augmentation conditionnelle du capital-actions décidée par l'assemblée générale du 28.05.2021 a été modifiée selon décision du 18.05.2022; pour les détails voir les statuts (art. 5b). La clause d'augmentation conditionnelle du capital-actions décidée par l'assemblée générale du 28.05.2021 a été modifiée selon décision du 18.05.2022; pour les détails voir les statuts (art. 5c). Statuts modifiés le 18.05.2022.

SHAB: 107 vom 03.06.2022
Tagesregister: 10207 vom 31.05.2022
Meldungsnummer: HR02-1005488606
Kantone: GE

1. Approval of the Annual Report, the Statutory Financial Statements and the Consolidated Financial Statements for Fiscal Year 2021. The Board of Directors proposes that the annual report, the statutory financial statements and the consolidated financial statements of ObsEva SA for fiscal year 2021 be approved.

2. Discharge of Liability for the Members of the Board of Directors and of the Executive Committee. The Board of Directors proposes that shareholders release the members of the Board of Directors and of the Executive Committee from liability for their activities during fiscal year 2021.

3. Appropriation of Financial Results. The Board of Directors proposes that the loss of USD 55,480,053 for the financial year 2021 be appropriated as follows:

Financial Year 2021

Accumulated losses brought forward from previous year

USD 328,451,570

Net loss for the year 2021

USD 55,480,053

Accumulated losses to be carried forward

USD 383,931,623

4. Elections to the Board of Directors and Election of the Chairperson of the Board of Directors. The Board of Directors proposes the re-election of the following nominees for a term of one year expiring at the closing of the 2023 Annual General Meeting:

4.1. Re-election of Annette Clancy as member of the Board of Directors and election as Chairperson of the Board of Directors

4.2. Re-election of Ernest Loumaye as member of the Board of Directors

4.3. Re-election of Brian O'Callaghan as member of the Board of Directors

4.4. Re-election of Anne VanLent as member of the Board of Directors

4.5. Re-election of Edward Mathers as member of the Board of Directors

4.6. Re-election of Catarina Edfjäll as member of the Board of Directors

Franciscus Verwiel is not standing for re-election.

The Board of Directors further proposes the election of the following nominee for a term of one year expiring at the closing of the 2023 Annual General Meeting:

4.7. Election of Stephanie Brown as member of the Board of Directors

Stephanie Brown is an accomplished executive leader with over 30 years of broad commercial experience in the bio-pharma industry. She currently serves as President North America for Santhera Pharmaceuticals, a global specialty pharmaceutical company focused on commercializing medicines for rare diseases. Over the course of her career, Stephanie has built and transformed businesses at organizations including Merck (MSD), Genentech, Biogen, and Novartis, where she held a variety of leadership roles in the USA, Canada and globally. She has deep experience in product launches and has successfully brought highly specialized, breakthrough biologics and small molecules from clinic to commercialization across a broad range of therapeutic areas.

Stephanie has chaired and governed inter-company collaborations, and has chaired, co-chaired and served on multiple executive US and global governance committees. She is a past member of the Board of Directors of the Biotechnology Innovation Organization, the biotechnology industry association in the USA. Stephanie has also served on the Operating Board of the West Island Palliative Care Residence, a non-profit organization located in Canada.

Stephanie has a BSc in Chemistry with Biology from Mount Allison University, Canada, and her MBA from Edinburgh Business School, University of Edinburgh, Scotland.

5.1. Re-election of Annette Clancy as member of the Compensation Committee

5.2. Re-election of Edward Mathers as member of the Compensation Committee

5.3. Re-election of Catarina Edfjäll as member of the Compensation Committee

6. Re-election of PricewaterhouseCoopers SA as ObsEva SA's Auditors and Independent Registered Public Accounting Firm. The Board of Directors proposes the re-election of PricewaterhouseCoopers SA as ObsEva SA's auditors and independent public accounting firm for the fiscal year 2022.

7. Re-election of Perréard de Boccard SA as Independent Representative. The Board of Directors proposes the re-election of Perréard de Boccard SA, Rue de la Coulouvrenière 29, 1204 Genève, as Independent Representative of shareholders for a one-year term expiring at the closing of the 2023 Annual General Meeting.

8. Compensation of the Board of Directors and the Executive Committee

8.1. Approval of the Compensation of the Board of Directors. The Board of Directors proposes that the shareholders approve a maximum aggregate amount of compensation of USD 2,500,000 for the members of the Board of Directors for the period from the 2022 Annual General Meeting to the 2023 Annual General Meeting.

8.2. Approval of the Compensation of the Executive Committee for the Fiscal Year 2023. The Board of Directors proposes that the shareholders approve a maximum aggregate amount of compensation of USD 15,000,000 for the members of the Executive Committee for the fiscal year 2023, subject to potential adjustment due to the fluctuation of the applicable exchange rate.

9. Increase of ObsEva SA's Authorized Share Capital. The Board of Directors proposes to increase to 54,310,230, the number of new ordinary shares that can be issued under the authorized share capital of ObsEva SA. For this purpose, the Board of Directors proposes to create a new authorized share capital, so that the Board of Directors be authorized to increase ObsEva SA's share capital until 18 May 2024, by the issuance of up to 54,310,230 new shares and, consequently, that a new Article 5a be introduced in ObsEva SA's Articles of Association accordingly.

10. Increase of ObsEva SA's Conditional Share Capital for Financing Purposes. The Board of Directors proposes to increase by 12,992,629, corresponding to an increase from 22,852,124 to 35,844,753, the number of new ordinary shares that can be issued upon exercise of option and conversion rights that may be granted in connection with bonds, similar debt instruments, loans or other financial market instruments or contractual obligations of the Company or one of its subsidiaries, and/or upon exercise of option rights issued by the Company or one of its subsidiaries, and that paragraph 1 of Article 5b of the Company's Articles of Association be consequently amended accordingly.

12. Approval of change to ObsEva SA’s Equity Incentive Plan. Subject to approval of Proposal 11: “Increase of ObsEva SA's Conditional Share Capital for Equity Plans”, in order to align the number of new ordinary shares that may be issued under the ObsEva SA's 2017 Equity Incentive Plan (the "Plan") with the number of new ordinary shares that can be issued as per Article 5c of ObsEva SA’s Article of Association, Conditional Share Capital for Equity Plans, as adopted by the shareholders, the Board of Directors proposes to the shareholders to increase by 4,707,365, from 13,880,413 to 18,587,778, the number of new ordinary shares that can be issued under the Plan, and to amend Article 3 (a) of the Plan accordingly. A copy of the Plan is available for download in the “Investors” section of our website (www.obseva.com).

13. Approval of Issuance of Conversion Shares and Warrant Shares under Securities Purchase Agreement. The Board of Directors proposes that the shareholders approve, for purposes of complying with Nasdaq Listing Rules 5635(b) and 5635(d), the issuance of common shares issuable upon the conversion of certain convertible notes and/or common shares issuable upon the exercise of certain warrants issued or issuable under the Company's Amended and Restated Securities Purchase Agreement, dated as of October 12, 2021, with certain funds and accounts managed by JGB Management, Inc.

For the Board of Directors

Franciscus Verwiel, Chairman of the Board

Mutation ObsEva SA

Rubrik: Handelsregistereintragungen
Unterrubrik: Mutation
Grund: Diverse Änderungen

ObsEva SA, à Plan-les-Ouates, CHE-253.914.856 (FOSC du 16.02.2022, p. 0/1005407580). Les pouvoirs de Renas David et Souverijns Wim sont radiés. Signature collective à deux a été conférée à Brown William, des USA, à Highlands Ranch, USA, Bührer Katja, d'Allemagne, à New York, USA, et Marro Luigi, de Bassins, à Nyon, directeurs.

SHAB: 71 vom 11.04.2022
Tagesregister: 6631 vom 06.04.2022
Meldungsnummer: HR02-1005448445
Kantone: GE

Mutation ObsEva SA

Rubrik: Handelsregistereintragungen
Unterrubrik: Mutation
Grund: Kapital neu

ObsEva SA, à Plan-les-Ouates, CHE-253.914.856 (FOSC du 26.07.2021, p. 0/1005258142). Augmentation autorisée du capital-actions, fondée sur la décision d'autorisation du 28.05.2021, porté de CHF 6'555'420, 85 à CHF 8'355'420, 85, par l'émission de 23'400'000 actions de CHF 1/13, nominatives.

Capital-actions:
CHF 8'355'420, 85, entièrement libéré, divisé en 108'620'471 actions de CHF 1/13, nominatives. Statuts modifiés le 11.02.2022. Vonderscher Jacky n'est plus administrateur; ses pouvoirs sont radiés.

SHAB: 33 vom 16.02.2022
Tagesregister: 2911 vom 14.02.2022
Meldungsnummer: HR02-1005407580
Kantone: GE

Mutation ObsEva SA

Rubrik: Handelsregistereintragungen
Unterrubrik: Mutation
Grund: Diverse Änderungen

ObsEva SA, à Plan-les-Ouates, CHE-253.914.856 (FOSC du 16.07.2021, p. 0/1005251804). Duncan Barbara, Healy Jim Irvin et Tordjman Rafaele Elisabete ne sont plus administrateurs; leurs pouvoirs sont radiés. O'Callaghan Brian Thomas, jusqu'ici directeur, nommé administrateur délégué, continue à signer collectivement à deux. Edfjäll Eva Catarina, de Suède, à Binningen et Vanlent Anne Marie, des USA, à Old Saybrook, USA, sont membres du conseil d'administration, avec signature collective à deux. Signature collective à deux a été conférée à Bertram Clive David, de Grande-Bretagne, à Farnham, GBR, directeur.

SHAB: 142 vom 26.07.2021
Tagesregister: 17883 vom 21.07.2021
Meldungsnummer: HR02-1005258142
Kantone: GE

Mutation ObsEva SA

Rubrik: Handelsregistereintragungen
Unterrubrik: Mutation
Grund: Kapital neu

ObsEva SA, à Plan-les-Ouates, CHE-253.914.856 (FOSC du 17.02.2021, p. 0/1005103897). L'assemblée générale a introduit une clause statutaire relative à une augmentation autorisée du capital-actions par décision du 28.05.2021. Pour les détails, voir les statuts. Par décision du 28.05.2021, l'assemblée générale a modifié la clause statutaire relative à l'augmentation conditionnelle du capital-actions en vue de financements introduite le 08.05.2019; pour les détails, voir les statuts. Par décision du 28.05.2021, l'assemblée générale a modifié la clause statutaire relative à l'augmentation conditionnelle du capital-actions pour les plans d'intéressement introduite le 09.06.2020; pour les détails, voir les statuts. Statuts modifiés le 28.05.2021. Augmentation conditionnelle du capital-actions, fondée sur la décision relative à l'octroi de droits du 28.05.2021, porté de CHF 6'247'728, 54 à CHF 6'555'420, 85 par l'émission de 4'000'000 actions de 1/13 de CHF 1, nominatives.

Capital-actions:
CHF 6'555'420, 85, entièrement libéré, divisé en 85'220'471 actions de 1/13 de CHF 1, nominatives. Statuts modifiés le 30.06.2021.

SHAB: 136 vom 16.07.2021
Tagesregister: 17004 vom 13.07.2021
Meldungsnummer: HR02-1005251804
Kantone: GE

1. Approval of the Annual Report, the Statutory Financial Statements and the Consolidated Financial Statements for Fiscal Year 2020. The Board of Directors proposes that the annual report, the statutory financial statements and the consolidated financial statements of ObsEva SA for fiscal year 2020 be approved.

2. Discharge of Liability for the Members of the Board of Directors and of the Executive Committee. The Board of Directors proposes that shareholders release the members of the Board of Directors and of the Executive Committee from liability for their activities during fiscal year 2020.

3. Appropriation of Financial Results. The Board of Directors proposes that the loss of USD 75,216,317 for the financial year 2020 be appropriated as follows:

Financial Year 2020

Accumulated losses brought forward from previous year

USD 253,235,253

Net loss for the year 2020

USD 75,216,317

Accumulated losses to be carried forward

USD 328,451,570

The Board of Directors informs the shareholders that the operating losses of the Company during financial year 2020, which were expected and are in line with the business plan of the Company, have led the Company to continue to be, as of December 31, 2020, in a situation of capital loss as per Article 725 paragraph 1 of the Swiss Code of Obligations, as the net assets of the Company no longer cover one-half of its share capital and legal reserves. The continuation of this situation was foreseen under the business plan of the Company, under which the Company is further expected, as a clinical-stage biopharmaceutical company, to undergo operating losses during financial years 2021 and 2022. The Company does not expect its situation of capital loss to affect its ability to carry out its activities on an ordinary basis and the Company's cash and cash equivalents, as at December 31, 2020, together with the funds raised in the first quarter of 2021, are expected to cover its operating expenses and capital expenditure requirements into mid-2022. The Board of Directors deems that no further corrective measures is to be taken by the shareholders for the time being.

4. Elections to the Board of Directors and Election of the Chairman of the Board of Directors. Our Board of Directors is presently composed of eight members each elected for a one-year term of office expiring at the closing of the 2021 Annual General Meeting. Jim Irvin Healy and Rafaele Elisabete Tordjman are not standing for re-election as members of the Board of Directors at the 2021 Annual General Meeting.

The Board of Directors proposes the re-election of the following nominees for a term of one year expiring at the closing of the 2022 Annual General Meeting:

4.1. Re-election of Franciscus Verwiel as member and Chairman of the Board of Directors

4.2. Re-election of Annette Clancy as member of the Board of Directors

4.3. Re-election of Barbara Duncan as member of the Board of Directors

4.4. Re-election of Ernest Loumaye as member of the Board of Directors

4.5. Re-election of Edward Mathers as member of the Board of Directors

4.6. Re-election of Jacky Vonderscher as member of the Board of Directors

The Board of Directors further proposes the election of the following nominees for a term of one year expiring at the closing of the 2022 Annual General Meeting:

4.7. Election of Catarina Edfjäll as member of the Board of Directors

Catarina Edfjäll is a Global Regulatory Affairs Expert with more than 25 years of experience in the biotech and pharma sector, now working as an independent consultant and mentor. She has profound drug development experience across the entire product lifecycle, from development to launch, and across many therapeutic areas, including rare diseases. She was responsible for the successful regulatory approval of 20 innovative medicinal products and new indications in more than 50 countries. In her most recent senior management role, Catarina was the global head of regulatory affairs at CSL Behring. Prior to that, she held leadership positions in regulatory affairs at companies formerly known as Actelion, Celgene and Shire, and, started her career at F. Hoffmann-La Roche.

Catarina is a Board Member at the Cancer Drug Development Forum (CDDF) and at the International Collaboration on Rare Diseases & Orphan Drugs (ICORD), both non-profit organisations. She has been actively involved in several multi-stakeholder organisations, including the European Medicines Agency´s Committee for Orphan Medicinal Products´ Working Group with Interested Parties.

Catarina holds a Master in biotechnology engineering from the Ecole Supérieure de Biotechnologie in Strasburg, a Ph.D. in biochemistry from the University in Basel and a Corporate Governance Certification from the Swiss Board School and the University of St Gallen.

The mandate of Catarina Edfjäll as member of the Board of Directors would only be effective as of June 30, 2021.

4.8. Election of Brian O’Callaghan as member of the Board of Directors

Brian O’Callaghan is a Life Science Executive with extensive experience within the biotech, big pharma and CRO sectors. He also has extensive global experience, having lived and worked in 5 different countries, as well as both sides of the US. He joined ObsEva in November 2020, as Chief Executive Officer to lead the Company through its future development, regulatory filings and product launches.

Prior to joining ObsEva, Brian has held CEO positions at Petra Pharma, Acucela, Sangart and BioPartners, as well as having held senior management positions at Pfizer, Merck Serono, Novartis, Covance and NPS Pharmaceuticals.

Brian has experience running both public and private companies, M&A’s, IPO’s, fundraising, divestments, spin-outs and strategic alliances. His operational experience is also wide ranging, having managed multiple businesses and programs, across many therapeutic areas, from concept through to commercialization. He also has extensive Board experience, having served on numerous biotech and 501c3 Boards.

5. Elections to the Compensation Committee. Our Compensation Committee is presently composed of four members each elected for a one-year term of office expiring at the closing of the 2021 Annual General Meeting. Jim Irvin Healy and Rafaele Elisabete Tordjman are not standing for re-election as members of the Compensation Committee at the 2021 Annual General Meeting.

The Board of Directors proposes the re-election of the following nominees for a term of one year expiring at the closing of the 2022 Annual General Meeting:

5.1. Re-election of Annette Clancy as member of the Compensation Committee

5.2. Re-election of Edward Mathers as member of the Compensation Committee

The Board of Directors further proposes the election of the following nominee for a term of one year expiring at the closing of the 2022 Annual General Meeting:

5.3. Election of Catarina Edfjäll as member of the Compensation Committee

The mandate of Catarina Edfjäll as member of the Compensation Committee would only be effective as of September 30, 2021.

6. Re-election of PricewaterhouseCoopers SA as ObsEva SA's Auditors and Independent Registered Public Accounting Firm. The Board of Directors proposes the re-election of PricewaterhouseCoopers SA as ObsEva SA's auditors and independent public accounting firm for the fiscal year 2021.

7. Re-election of Perréard de Boccard SA as Independent Representative. The Board of Directors proposes the re-election of Perréard de Boccard SA, Rue de la Coulouvrenière 29, 1204 Genève, as Independent Representative of shareholders for a one-year term expiring at the closing of the 2022 Annual General Meeting.

8. Compensation of the Board of Directors and the Executive Committee

8.1. Approval of the Compensation of the Board of Directors. The Board of Directors proposes that the shareholders approve a maximum aggregate amount of compensation of USD 2,500,000 for the members of the Board of Directors for the period from the 2021 Annual General Meeting to the 2022 Annual General Meeting.

8.2. Approval of the Compensation of the Executive Committee for the Fiscal Year 2022. The Board of Directors proposes that the shareholders approve a maximum aggregate amount of compensation of USD 13,000,000 for the members of the Executive Committee for the fiscal year 2022, subject to potential adjustment due to the fluctuation of the applicable exchange rate.

9. Increase of ObsEva SA's Authorized Share Capital. The Board of Directors proposes to increase to 40,610,232, the number of new ordinary shares that can be issued under the authorized share capital of ObsEva SA. For this purpose, the Board of Directors proposes to create a new authorized share capital, so that the Board of Directors be authorized to increase ObsEva SA's share capital until 28 May 2023, by the issuance of up to 40,610,232 new shares and, consequently, that a new Article 5a be introduced in ObsEva SA's Articles of Association accordingly.

10. Increase of ObsEva SA's Conditional Share Capital for Financing Purposes. The Board of Directors proposes to increase to 13,325,051, corresponding to an increase from 13,527,073 to 26,852,124, the number of new ordinary shares that can be issued upon exercise of option and conversion rights that may be granted in connection with bonds, similar debt instruments, loans or other financial market instruments or contractual obligations of the Company or one of its subsidiaries, and/or upon exercise of option rights issued by the Company or one of its subsidiaries, and that paragraph 1 of Article 5b of the Company's Articles of Association be consequently amended accordingly.

12. Approval of change to ObsEva SA’s Equity Incentive Plan. Subject to approval of Proposal 11: “Increase of ObsEva SA's Conditional Share Capital for Equity Plans”, in order to align the number of new ordinary shares that may be issued under the ObsEva SA's 2017 Equity Incentive Plan (the "Plan") with the number of new ordinary shares that can be issued as per Article 5c of ObsEva SA’s Article of Association, Conditional Share Capital for Equity Plans, as adopted by the shareholders, the Board of Directors proposes to the shareholders to increase by 4,753,671, from 9,126,742 to 13,880,413, the number of new ordinary shares that can be issued under the Plan, and to amend Article 3 (a) of the Plan accordingly. A copy of the Plan is available for download in the “Investors” section of our website (www.obseva.com).

For the Board of Directors

Franciscus Verwiel, Chairman of the Board

Mutation ObsEva SA

Rubrik: Handelsregistereintragungen
Unterrubrik: Mutation
Grund: Kapital neu

ObsEva SA, à Plan-les-Ouates, CHE-253.914.856 (FOSC du 03.02.2021, p. 0/1005091294). Augmentation conditionnelle du capital-actions, fondée sur la décision relative à l'octroi de droits du 08.05.2019, porté de CHF 5'094'066, 69 à CHF 5'356'103, 62 par l'émission de 3'406'480 actions de 1/13 de CHF 1, nominatives. Augmentation autorisée du capital-actions, fondée sur la décision d'autorisation du 09.06.2020, porté de CHF 5'356'103, 62 à CHF 6'247'728, 54 par l'émission de 11'591'124 actions de CHF 1/13 de CHF 1, nominatives.

Capital-actions:
CHF 6'247'728, 54, entièrement libéré, divisé en 81'220'471 actions de 1/13 de CHF 1, nominatives. Suppression de la clause statutaire relative à l'augmentation autorisée du capital-actions, fondée sur la décision d'autorisation du 09.06.2020, le montant de l'augmentation ayant été atteint. Statuts modifiés le 12.02.2021. Les pouvoirs de Bestel Elke et de Tan Tek Goan sont radiés. Signature collective à deux a été conférée à Garner Elizabeth Ijeoma Onyemelukwe, des USA, à Bryn Mawr, USA, directrice, O'Callaghan Brian Thomas, des USA, à San Diego, USA, directeur, et Renas David, des USA, à San Diego, USA, directeur.

SHAB: 33 vom 17.02.2021
Tagesregister: 3489 vom 15.02.2021
Meldungsnummer: HR02-1005103897
Kantone: GE

Mutation ObsEva SA

Rubrik: Handelsregistereintragungen
Unterrubrik: Mutation
Grund: Kapital neu

ObsEva SA, à Plan-les-Ouates, CHE-253.914.856 (FOSC du 01.10.2020, p. 0/1004990719). Augmentation autorisée du capital-actions, fondée sur la décision d'autorisation du 09.06.2020, porté de CHF 4'630'970, 69 à CHF 5'094'066, 69 par l'émission de 6'020'248 actions de 1/13 de CHF 1, nominatives.

Capital-actions:
CHF 5'094'066, 69, entièrement libéré, divisé en 66'222'867 actions de 1/13 de CHF 1, nominatives. Statuts modifiés le 29.01.2021.

SHAB: 23 vom 03.02.2021
Tagesregister: 2319 vom 01.02.2021
Meldungsnummer: HR02-1005091294
Kantone: GE

Mutation ObsEva SA

Rubrik: Handelsregistereintragungen
Unterrubrik: Mutation
Grund: Kapital neu

ObsEva SA, à Plan-les-Ouates, CHE-253.914.856 (FOSC du 10.09.2020, p. 0/1004976512). Augmentation autorisée du capital-actions, fondée sur la décision d'autorisation du 09.06.2020, porté de CHF 4'591'251.31 à CHF 4'630'970.69 par l'émission de 516'352 actions de 1/13 de CHF 1, nominatives.

Capital-actions:
CHF 4'630'970.69, entièrement libéré, divisé en 60'202'619 actions de 1/13 de CHF 1, nominatives. Statuts modifiés le 22.09.2020.

SHAB: 191 vom 01.10.2020
Tagesregister: 16613 vom 29.09.2020
Meldungsnummer: HR02-1004990719
Kantone: GE